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Abstract
Background & Aims
Expression of liver progenitor cell (LPC) characteristics has been proposed as a negative
prognostic marker in primary liver tumors. Hypoxia has been linked to activation of the
Notch pathway which is responsible for activation and proliferation of LPCs and hypoxia-in-
duced LPC activation has been shown in hepatocellular carcinoma. Our aim was to eluci-
date the time-dependent effects of hypoxia on the LPC niche in hepatocellular carcinoma
which could aid in determining a safe time frame for use of hypoxia inducing therapies.
Methods
We used dimethyloxaloylglycine to mimic a hypoxic reaction in mice by stabilizing hypoxia-
inducible factor 1 alpha at three distinct time points in diethylnitrosamine induced hepatocar-
cinogenesis. LPC, metastasis and Notch pathway markers were determined by quantitative
PCR and (immune)histochemistry (heamatoxillin-eosin, reticulin, Sirius red and cytokeratin
19 staining).
Results
Activating the hypoxia inducible pathway early in hepatocarcinogenesis resulted in an in-
creased incidence of both cholangioma and hepatocellular lesions, associated with high ex-
pression of LPC, metastatic and Notch pathway markers. Adversely, activating the hypoxic
response during tumor development resulted in decreased incidence of hepatocellular le-
sions and increased cholangioma incidence, with an unaltered gene expression profile of
LPC-, Notch pathway- and metastatic markers. A hypoxic insult at advanced stages of
hepatocarcinogenesis severely increased the expression of LPC characteristics, however
without increased expression of actors of the Notch pathway and metastatic markers and
minor changes in incidence of hepatocellular and cholangioma lesions.
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Conclusion
Our results indicate that increased hypoxia at the onset of tumor development has detrimen-
tal effects on tumor progression; patients with HCC developed in a background of fibrosis/
cirrhosis might therefore represent a more difficult treatment group. In contrast, hypoxia dur-
ing tumor development appears to favor tumor outcome, highlighting the importance of
early detection. Finally, hypoxia in advanced stages resulted in increased expression of
LPC characteristics indicating poor outcome.
Introduction
Primary liver tumors, especially hepatocellular carcinoma (HCC), often develop in a back-
ground of chronic liver disease, characterized by fibrosis and eventually cirrhosis. This process
is accompanied by increased hypoxia, caused by sinusoidal capillarization and formation of fi-
brotic septa, increasing resistance to blood flow and thus decreasing oxygen delivery to liver
cells [1]. In addition, fast growing liver tumors quickly outgrow the existing liver vasculariza-
tion and newly formed intra-tumoral vessels are often structurally and functionally abnormal
[2]. Ideally, applied anti-angiogenic treatment inhibits further extension of this poorly struc-
tured blood supply, depriving tumor cells of oxygen resulting in growth arrest [3, 4]. However,
this intra-tumoral hypoxia, can also result in inhibition of prolyl hydroxylase domains (PHD),
leading to stabilization of the hypoxia inducible factor 1 alpha (HIF-1α) resulting in transacti-
vation of a plethora of genes such as the pro-angiogenic vascular endothelial growth factor
alpha (Vegfa), and members of the glycolytic pathway such as glucose transporter 1 (Glut1)
and phosphofructokinase (Pfk) aiding tumor cell survival [2, 4]. Therapy resistance to sorafe-
nib has been linked to increased HIF signalization and anti-angiogenic treatment has been
identified to cause increased local invasion and metastasis, worsening tumor progression [5–8].
Liver progenitor cells (LPCs) reside in the canals of Hering and are activated upon severe
acute or chronic hepatic injury [9]. These bipotential progenitor cells proliferate and migrate
towards the site of injury to replace hepatocytes and/or cholangiocytes and restore liver func-
tion. Interest in the role of LPCs in liver disease pathogenesis has recently expanded [9–15]
and the knowledge that Notch andWnt signaling drive LPC differentiation towards cholangio-
cytes or hepatocytes respectively has opened new perspectives into the regulation of hepatic
cell differentiation[10, 15].
Several other pathways, including the HIF-1α-pathway have been linked to differential LPC
behavior in liver disease and cancer [14]. For example: exposure of HCC cells to hypoxia signif-
icantly increased stem cell marker expression in vitro which could account for the observed
dedifferentiation in tumors with low oxygen supply [16]. Interestingly, PHD2 haplodeficient
mice, in which the HIF-dependent pathway is continuously activated, show increased cholan-
giocarcinoma (CC) burden, coinciding with increased expression of liver progenitor cell (LPC)
markers after diethylnitrosamine (DEN) induced HCC induction [17]. Additionally, TACE
treatment is also able to switch tumor phenotype from HCC to mixed HCC-CC, with increased
expression of LPC markers, a more aggressive character and worse prognosis compared to
HCC [18, 19].
Treatment induced hypoxia may thus increase the expression of stem/progenitor character-
istics, which can mediate tumor progression, invasion, metastasis, therapy resistance, early
post-operative recurrence and induce a phenotypic switch [5, 6, 8, 17–24]. Elucidating the time
points in hepatocarcinogenesis at which activation of the hypoxic pathway has detrimental
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effects with respect to tumor outcome may allow us to anticipate and adapt current therapeutic
strategies. Therefore, we assessed the time dependent consequences of elevated HIF signaling
on tumor progression and LPC activation by using the PAN-PHD inhibitor dimethyloxaloyl-
glycine (DMOG) in an orthotopic HCC mouse model.
Materials and Methods
Primary tumor induction and dimethyloxaloylglycine (DMOG) mediated
activation of the HIF pathway
Ethics statement. All experiments were evaluated and approved by the Ghent University,
faculty of health and medicine’s ethical commission for animal testing (ECD 12/57) and all ef-
forts were made to minimize animal discomfort.
Weekly intraperitoneal (IP) DEN (Sigma—Aldrich, Bornem, Belgium) injections (35mg/kg)
are known to induce neoplastic regions after 16 weeks, HCC nodules after 20 weeks and HCC
with 100% penetrance from 25 weeks on [2]. For this study we administered DEN for 22 weeks
in 5-week-old male 129S2/svPasCrl mice, control mice received weekly doses of saline equiva-
lent to DEN counterparts.
Dose and interval of DMOG, which has been shown to induce HIF-1α stabilization [25],
was first tested for its ability to effectively induce functional HIF-1α by measuring the transac-
tivation of Vegfa, Glut1 and Pfk. Mice received a single IP DMOG injection (4,8mg/20g) fol-
lowed by euthanasia after 3 and 7 days. Livers were removed and sections were lysed for RNA
extraction and qPCR. Results showed that biweekly DMOG injections effectively induce HIF
activation (Fig. 1A) and this treatment strategy was further applied.
DEN-treated mice received DMOG or PBS for five weeks at three different time points dur-
ing tumor development: at early (1–5 weeks), intermediate (Int, 16–22 weeks) and advanced
(Adv, 22–27 weeks) stages. For comparability between intermediate and advanced treatment
groups and to reduce bias by acute DMOG effects, we chose to sacrifice mice from these groups
7 days after the final DMOG injection. saline control mice received DMOG from week 16 to
22 or from week 22 to 27 and were sacrificed after respectively 22 or 27 weeks
Scarification was preceded by anesthesia of the mice with isoflurane (Florene, Abbott,
Hoofddorp, the Nederlands) in oxygen for weighting and blood sampling from the ophthalmic
artery. After cervical dislocation, the liver was prelevated and weighed. Part of the liver was
emerged in RNA later (Ambion, Gent, Belgium) and snap frozen. Remaining tissue was incu-
bated in 4% phosphate buffered formaldehyde (KP4078.9010 Klinipath, Olen, Belgium) and
imbedded in paraffin, as previously described [1, 2, 7].
Immunohistological analyses
Hematoxilin-eosin (H&E) staining was performed as previously described [26] and sections
were analyzed by a pathologist for general morphology and neoplasticity based on the follow-
ing characteristics: enlarged cells with normal nucleus to cytoplasm ratio (n/c), small cells with
increased n/c, enlarged pleomorphic nuclei, and binucleation.
Sirius red staining was performed as routinely described [26] to assess fibrosis which allows
distinction between areas of ductular proliferation and cholangioma characterized by presence
of typical cholangiofibrosis [7, 17].
Reticulin staining was performed to evaluate the presence of HCC nodules [26], which are
absent for reticulin.
HIF-1α stabilization was evaluated through immunohistochemistry, using a rabbit anti—
HIF-1α antibody (sc-10790, 1/400 in PBS, RRID: AB_2116990, Santa Cruz biotechnology,
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INC, California USA). Cytokeratin 19 (CK19) staining was performed to visualize structures of
the cholangiocytic lineage, including LPCs, using monoclonal rabbit anti-CK19 (1/200 in TBS,
ab133496, RRID:AB_11155282, abcam, Cambridge, UK). Epithelial cell adhesion molecule
(Epcam) expression was examined using a goat polyclonal antibody raised against the tran-
scriptionally active intracellular domain of Epcam (sc-23788, 1/300 in PBS, RIDD:
AB_2098653, Santa Cruz biotechnology, INC, California, USA). LSAB- horseradish peroxi-
dase-mediated visualization (K0690, DAKO, Heverlee, Belgium) was performed for all proto-
cols. Overall immunoreactivity was calculated using Cell D software (Olympus Imaging
Solutions, Münster, Germany) to assess increased expression of all cells of the cholangiocytic
lineage. Since cholangiocytes organize in ductular structures and LPCs occur as singular cells,
5 portal areas were centered at a magnification of 400 and all CK19+ single cells were counted.
Quantitative real time PCR (qPCR)
RNA was extracted from 20 mg of frozen liver tissue preserved in RNA-later, according to the
manufacturer’s guidelines (Rneasy Mini Kit, Quiagen, Venlo, the Nederlands).
cDNA was obtained from 1μg RNA using the iScript cDNA synthesis kit (Bio-Rad, Naza-
reth-Eke, Belgium) and real time quantitative PCR (RT-qPCR) analyses were performed using
the Lightcycler 480 Green I master mix (Roche, Vilvoorde, Belgium).
Primer sets are listed in S1 Table, their efficiency was calculated from the slope of a standard
curve using the following formula: E ¼ 10 1slope  1. All reactions were run in duplicate and nor-
malized to reference genes that showed stable expression in all samples. The comparative Ct
method was used to determine the number of transcripts.
Statistics
Data were analyzed using SPSS21 software (IMB corp, Armonk NY, USA). Kolmogorov-Smir-
nov test was used to test for normality. Student’s T- test was then performed in case of normali-
ty; the Mann-Whitney-U test was used for not normally distributed data. P-values0,05
where considered significant. All data are presented as average ±SEM.
Results
Time dependent effect of HIF stabilization on DEN-induced
tumorigenesis
We first analyzed whether 4,8mg/20g biweekly or weekly DMOG injections are required to
maintain stable activation of the HIF-pathway in livers, by performing qPCR analysis of HIF
sensitive genes like Vegfa, Glut1 and Pfk. There was an increased expression of HIF sensitive
genes, for at least 3 but not 7 days, significant for Vegf and Pfk after DMOG induction, com-
pared to PBS control (Fig. 1A). Further treatment regimes were therefore carried out by bi-
weekly DMOG injections.
To assess the effect of HIF stabilization early on in tumorigenesis, DMOG was administered
during the first 5 weeks of DEN treatment (Early). Samples were taken after 22 weeks, early
DMOG treatment had no effect on relative liver weight (Fig. 2A). Sirius red staining revealed
Fig 1. Hypoxia inducible factor expression. A: Expression of HIF-1α target genes, characteristic for stabilization of HIF-1α, 3 and 7 days after single
DMOG injection B. Representative images of HIF-1α staining, showing HIF stabilization in all DEN groups, mostly located in and around cholangioma and
HCC lesions and near portal areas.C. mRNA expression for HIF-1αmarkers. For animals sacrificed after 22 weeks; saline Ctrl: n = 8, PBS Ctrl: n = 6, Early
DMOG: n = 8, Int DMOG: n = 6 and for animals sacrificed after 27 weeks; saline Ctrl: n = 8, PBS Ctrl: n = 7, Adv DMOG: n = 7. Scale bars: 200μm, *: p<0,05;
**p<0,01 Hif-1α: hypoxia inducible factor 1 alpha, DMOG: dimethyloxaloylglycine, DEN: diethylnitrosamine.
doi:10.1371/journal.pone.0119555.g001
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Fig 2. General parameters. A: Liver/ bodyweight ratios for all groups B: Prevalence of cholangioma and hepatocellular lesions, showing percentage of mice
showing one or more cholangioma or (premalignant) HCC lesionsC:Representative images of Sirius red and reticulin staining showing cholangioma lesions
in all DMOG groups except for PBS control after 22 weeks, and HCC lesions in all DEN groups except for the Int. DMOG group. Scale bars: 200μm,
*: p<0,05; **p<0,01. DMOG: dimethyloxaloylglycine; DEN: diethylnitrosamine
doi:10.1371/journal.pone.0119555.g002
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cholangioma formation in 37,5% and reticulin staining showed premalignant HCC lesions in
62,5% of mice compared to respectively 0 and 50% of the mice receiving PBS (Fig. 2B, C).
To evaluate the activation of the hypoxic pathway during intermediate stages, DMOG was
injected from week 16 to week 22 (intermediate, Int.) during DEN induction. Samples were
taken at the end of week 22, Int. DMOG also did not influence relative liver weight (Fig. 2A).
Sirius red and reticulin staining in Int. DMOG-treated animals showed cholangioma formation
in 50% of DMOG injected mice and no HCC lesions, compared to no cholangioma lesions and
50% HCC lesions in PBS control mice (Fig. 2B, C).
For the effect of HIF stabilization after the final DEN injection, during tumor growth,
DMOG (or PBS) was administered from week 22 to 27 (advanced, Adv.) and samples were
taken fter27 weeks. Adv. DMOG resulted in a significantly increased relative liver weight com-
pared to PBS counterparts (Fig. 2A). Sirius red staining showed cholangioma lesions in 50% of
PBS and 66,7% of DMOG induced animals and reticulin staining showed HCC lesions in 40%
of DMOG and 50% of PBS treated livers (Fig. 2B, C).
This suggests that, Early Int. and Adv. DMOG result in increased cholangioma formation
and Early DMOG even increases HCC formation, while Int. DMOG inhibits HCC formation.
Immunohistochemistry and qPCR analysis were then performed to assess HIF-1α stabiliza-
tion and activity after Early, Intermediate and Advanced DMOG treatment. While HIF-1α
immunopositivity was limited in saline control livers, in DEN treated livers there was some cy-
toplasmic presence of the HIF protein in hepatocytes and cholangiocytes around the portal
area, but immunopositivity was mostly observed in and around hepatocellular and cholan-
gioma lesions (Fig. 1B).
HIF-1α activity was determined through qPCR analysis for downstream HIF target genes.
As expected, there was no increased expression in Int.—and Adv. DMOG groups compared to
their PBS control groups (Fig. 1C). Strangely, these DEN groups also show no increased or
even a decreased expression of HIF-dependant genes compared to saline control. However, we
do see significantly increased mRNA expression of HIF target genes Glut1 and Vegfa in DEN
livers after Early DMOG treatment compared to all other groups(Fig. 1C).
Time dependent effect of hypoxia on LPC characteristics in DEN treated
mice
Tumor sections were analyzed for overall CK19 immunopositivity, which is a marker for bili-
ary epithelial cells, including LPCs. All animals receiving DEN showed increased immunoposi-
tivity for CK19 after 22 weeks compared to saline controls. (Fig. 3A and B left graph). Mice
treated with DMOG at advanced stages showed significantly enhanced CK19 immunopositiv-
ity compared to PBS control (Fig. 3A and B right graph). CK19+ single cells (Fig. 3C) were nu-
merous in livers of DEN treated groups compared to saline controls at 22 weeks (p<0,05), but
no significant difference was seen between treatment regimes (Fig. 3D upper graph). DMOG
treatment from week 22–27 did however result in a significant increase in CK19+ single cells
compared to both PBS and saline control groups (Fig. 3D lower graph).
Next, we examined sections for Epcam immunopositivity, which is a marker for biliairy epi-
thelial cells, including LPCs[27] as well as tumor cells[28]. In saline control mice, staining was
limited to cholangiocytes and some membranous staining of hepatocytes (Fig. 4A). In DEN
treated mice immunopositivity was seen in the cytoplasm of hepatocytes, mostly around portal
areas and in regions containing cholangioma -and hepatocellular lesions (Fig. 4A). These re-
sults were in line with those of CK19, with a positive trend to increased Epcam expression for
all DEN mice, significant for all DMOG groups and for mice that received PBS from week 22
to 27 compared to saline control (Fig. 4B). Futhermore, Adv. DMOG treatment also resulted in
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Fig 3. Cytokeratin 19. A: Representative images of overall CK19 staining, early DMOG and PBS counterparts also show cytoplasmatic staining in
hepatocytes B: quantified % of overall CK19 staining after 22 and 27 weeksC: Image of portal area at 400x magnification as used to count single cells,
arrowheads point to single cells D: Average number of single cells per portal area for each group. Scale bars: 200μm, *p<0,05, **p<0,01. #p<0,05,
##p<0,01 compared to all other groups. CK19: cytokeratin 19; DMOG: dimethyloxaloylglycine
doi:10.1371/journal.pone.0119555.g003
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a significantly increased Epcam immunopositivity compared to PBS control after 27 weeks
(Fig. 4B).
Since progenitor cell markers have been proposed as markers of poor prognosis in HCC, we
next examined the mRNA expression of liver progenitor cell markers cytokeratin 7 (CK7),
CK19, CD44, alpha-fetoprotein (Afp), Epcam and prominin1 (Prom1). In DEN mice receiving
DMOG at early stages, there was a non-significant increased expression of CK7, CK19, Epcam
and Prom1, compared to PBS control, wich was not seen in mice treated with DMOG at inter-
mediate stages (Fig. 5A). Suggesting a protective role for Int. DMOG and a previously unre-
ported effect of early hypoxia. Afp expression was significantly increased after both early and
intermediate DMOG treatment compared to PBS control (Fig. 5A).
Adv. DMOG resulted in a non-significant increase of all markers, except for CK7 where a
non-significant decreased expression was seen, compared to PBS control. Both DEN groups
showed increased expression of LPC markers compared to saline control (all significant for
Adv. DMOG group, significant for Prom1, CK7 and CK19 for PBS group), (Fig. 5B).
Since Notch signaling is known to be involved in the differentiation of LPCs to cholangio-
cytes, and has also been suggested to mediate hypoxia induced therapy resistance and increased
Fig 4. Epithelial Cell Adhesion Molecule. A. quantified % of Epcam intracellular domain staining after 22 and 27 weeksB. representative images of Epcam
staining showing presence around cell membranes of hepatocytes and in cytoplasm of cholangiocytes in saline control livers (upper left). In DEN treated
livers, cytoplasmic expression in hepatocytes around portal areas, cholangioma -and hepatocellular lesions was increased. Scale bars: 200μm *:p<0,05;
**p<0,01. Epcam: epithelial cell adhesion molecule; DEN: diethylnitrosamine
doi:10.1371/journal.pone.0119555.g004
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invasion/metastasis [14], we examined mRNA levels of Notch 1, Notch 2 and Notch3 recep-
tors, the ligand Jagged1 and main target gene: hairy enhancer of split 1 (Hes1); and matrix
metalloproteinase 9 (Mmp9) and Integrin alpha 5 (ItgaV) as markers for metastasis [29]. Inter-
estingly, Notch and metastasis markers were only up-regulated in mice that received DMOG at
early stages (Fig. 6). Table 1 summarizes the main findings for all groups.
Discussion
In the present study, we show that pan-PHD inhibition in early and advanced stages of hepato-
carcinogenesis induces increased expression of LPC characteristics, while PHD inhibition in
intermediate stages has a tendency to decrease the expression of LPC characteristics. Further-
more, the early, but not intermediate or advanced-stage HIF-1α stabilization, concurred with
increased expression of actors of the Notch pathway and metastatic markers. These results in-
dicate an important time- dependent effect of hypoxic stimuli in HCC and a previously unde-
scribed detrimental delayed effect of an early hypoxic event on tumor development.
Fig 5. mRNA expression of LPCmarkersA: mRNA expression of LPCmarkers after early and Int.DMOGB:mRNA expression of LPCmarkers after
Adv. DMOG. *:p<0,05; **p<0,01, ##<0,01. DMOG: dimethyloxaloylglycine; LPC: liver progenitor cell
doi:10.1371/journal.pone.0119555.g005
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Currently LPCs are being intensively studied for their role in various liver diseases, and
have recently also been implicated in the pathogenesis of primary liver tumors. Increased ex-
pression of LPC characteristics serves as a marker for poor prognosis [21, 23, 24, 30]. More-
over, since LPCs highly express multi drug resistance proteins, they are also implicated in
therapy resistance [31]. Furthermore, different studies have shown a phenotypic switch from
HCC to HCC-CC following hypoxic stimuli, coinciding with increased expression of
Fig 6. mRNA expression of Notch andmetastasis markers. A:mRNA expression of Notch and metastasis markers after early and Int. DMOGB:mRNA
expression of Notch and metastasis markers after Adv. DMOG in DEN induced hepatocellular carcinoma. *p<0,05; **p<0,01, ## p<0,01 compared to all
other groups. DMOG: dimethyloxaloylglycine; DEN: diethylnitrosamine
doi:10.1371/journal.pone.0119555.g006
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Table 1. Summary of groups and major ﬁndings.
Timing DMOG Early intermediate advanced
week 1–5 week 16–22 week 22–27
DEN induction 22 weeks
Total time 22 weeks 27 weeks
DEN control group 22w DEN + 22w DEN +
PBS (week16–22) PBS (week 22–27)
General parameters
relative liver weight ⇵ ⇵ "*
1,039 ± 0,02798 1,167 ± 0,06543 1,321 ± 0,07186
Tumor type
Hepatocellular lesions " # #
Cholangioma " " "
Liver progenitor cell markers
CK19+ single cells ⇵ # "*
1,036 ± 0,1279 0,7589 ± 0,1511 4,179 ± 1,012
CK19 mRNA " # "
2,172 ± 0,9123 0,2844 ± 0,1336 5,711 ± 1,423
CK7 mRNA " # #
3,020 ± 0,9846 0,3080 ± 0,1281 8,932 ± 2,806
Prom1 mRNA " # "
2,973 ± 1,044 0,4728 ± 0,1257 1,972 ± 0,4273
Epcam mRNA " # "
1,337 ± 0,4107 0,5967 ± 0,1828 14,29 ± 3,995
CD44 mRNA # # "
0,8260 ± 0,1985 0,6499 ± 0,08237 4,075 ± 1,909
Afp mRNA "** "* "
5,978 ± 2,008 1,912 ± 0,5875 2,913 ± 1,338
Notch markers
Notch1 mRNA "* ⇵ "
2,096 ± 0,02613 1,185 ± 0,08566 1,460 ± 0,2858
Notch2 mRNA " ⇵ ⇵
1,807 ± 0,2696 0,8063 ± 0,1477 0,8674± 0,05704
Notch3 mRNA " ⇵ #
1,543 ± 0,2627 0,9848 ± 0,2933 0,6119 ±0,09868
Jagged1 mRNA " " #
2,633 ± 0,5159 1,529 ± 0,2996 0,8272 ± 0,2529
Hes1 mRNA ⇵ #* ⇵
0,8795 ± 0,1181 0,4431 ± 0,04125 0,9004 ± 0,2051
Metastatic markers
MMP9 mRNA " ⇵ ⇵
2,688 ± 0,8184 0,8170 ± 0,2145 0,8541 ± 0,1239
ItgaV mRNA "* ⇵ ⇵
3,063 ± 0,9327 0,9311 ± 0,2445 0,7502 ± 0,3067
First row: ⇵: No change compared to DEN control, ": Increase compared to DEN control, #: Decrease compared to DEN control. Second row: fold
changes ±Standard deviation, compared to PBS control.
*: p<0,05
**: p<0,01
doi:10.1371/journal.pone.0119555.t001
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progenitor cell markers [6, 17, 18]. Since activation of the hypoxic pathway could alter LPC be-
havior in hepatocellular carcinoma, we studied the effect of increased activation of HIF on
DEN induced hepatocarcinogenesis.
We used DMOG to induce the hypoxic response, aimed at mimicking oxygen deprivation
at different time points in tumor development. The early HIF stabilization reflects patients
with chronic liver disease, characterized with fibrotic strands and hypoxia prior to tumor devel-
opment. Additionally, early HIF stabilization may also mimic hypoxia-inducing treatment
strategies affecting recurrent tumor behavior. The intermediate DMOG induction relates to pa-
tients undergoing anti-angiogenic treatment for early stage cancer. Lastly, the group receiving
DMOG at advanced stages resembles patients receiving treatment for advanced stage HCC.
Immunohistochemistry for HIF-1α expresssion showed few hepatocytes expressing HIF in
saline groups, and cells expressing the HIF protein in DEN groups were mostly residing in the
portal area, and in and around hepatocellular- and cholangioma lesions, coinciding with CK19
and Epcam immunopositive regions.
Our aim was not to show HIF-1α stabilization following DMOG at specific time points but
to evaluate its effect on tumorigenesis and LPC activation on the long term. We therefore
chose to euthanize mice 7 days after the final DMOG injection which is confronted with an at-
tenuation of HIF-1α stabilization and transcriptional activation as shown in by the single
DMOG injection experiment. Activation of the HIF pathway in DEN groups was examined
through qPCR analysis of HIF-1α target genes, no difference could be detected between inter-
mediate and advanced DMOG and their respective PBS controls, confirming that acute effects
of PHD inhibition were eliminated by euthanizing animals 7 days after the final DMOG
injection.
Strangely, saline groups had an equal Glut1 and Pfk and even an increased Vegfa mRNA ex-
pression compared to intermediate and advanced DMOG groups and their PBS controls. Since
saline mice had also received DMOG, possibly a variety of feedback loops could be differential-
ly regulated in DEN compared saline mice [32, 33], which should be further investigated.
Interestingly, the DEN group that received DMOG at early stages, did show significantly in-
creased expression Vegfa and Glut1 compared to other groups. HIF induction early in DEN-
induced hepatocarcinogenesis also caused increased formation of cholangioma and HCC le-
sions as well as a massive upregulation of LPC features and metastatic markers on the RNA
level, compared to groups that received DMOG or PBS at intermediate stages. This massive de-
layed effect of hypoxia has not previously been described and indicates that early hypoxia
could readily prepare cells for later tumor growth and growth—induced hypoxia, resulting in
tumors with a more aggressive phenotype.
Thus, monitoring the extent to which the hypoxic pathway is activated after hypoxic treat-
ment for recurring tumors or as a result of inflammation and fibrosis in chronic liver disease
could have prognostic value when these patients (re)develop HCC later on. Indeed, there is evi-
dence of a phenotypic switch in tumors recurring after TACE, which induces a massive hypox-
ic response [18, 19].
Mice receiving DMOG during tumor development (at intermediate stages) displayed no
HCC lesions and no altered expression of LPC or metastatic markers compared to PBS control
mice. While the increased formation of cholangioma lesions should be monitored, these benign
intrahepatic bile duct adenomas usually do not require treatment [34]. Taken together, this
could point to a safe therapeutic window for hypoxia inducing treatment after early detection.
Administering the pan-PHD inhibitor DMOG in advanced stages of tumor development re-
sulted in a significantly increased relative liver weight, a slight decrease in HCC and a minor in-
crease in cholangioma lesions coinciding with a significantly increased expression of LPC
markers and number of CK19+ single cells. This observation is in line with previous reports
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showing that treatment induced hypoxia is linked to an increased expression of stem/progeni-
tor characteristics [16, 35, 36]. However, while this hypoxia-induced LPC signature did not co-
incide with increased expression of metastatic markers, HCC lesions with a cholangiocytic
signature have been linked to poor prognosis and early recurrence [20–24, 30, 37]. Further-
more, while the increased relative liver weight compared to PBS counterparts is at least partly
caused by the increased amount of cholangioma and its accompanying cholangiofibrosis, it
could also be a sign of increased tumor burden.
Notch signalization is involved in LPC proliferation and pushes LPC differentiation towards
cholangiocytic structures. Since we observed an increased incidence of cholangioma lesions in
DEN- livers after a hypoxic insult, RNA expression of Notch related genes was analyzed. In-
creased mRNA expression of actors of the Notch pathway was seen in livers of mice receiving
DMOG early in hepatocarcinogenesis coinciding with high expression of LPC- and
metastatic markers.
This suggests a role for Notch- mediated increased proliferation of LPCs and differentiation
towards cholangiocytes in the pathogenesis of HCC after early hypoxic stimuli, thus contribut-
ing to the development or recurrence of aggressive, more invasive tumors with a mixed pheno-
type. Indeed, pharmacological inhibition of the Notch pathway has already been proven to be
effective in reducing the amount of chemo-resistant cancer stem cells in breast and colon can-
cer [38, 39]. Surprisingly, DMOG administration at both intermediate and advanced stages did
not lead to increased expression of actors of the Notch pathway.
While CK19 and CK7 positive liver tumors have been proposed to be progenitor cell derived
[37], in vitro experiments have shown that HCC cells are capable of trans differentiating to-
wards a cholangiocytic phenotype [40, 41]. The fact that the stem cell marker Prom1 is only
marginally up-regulated compared to the pronounced cholangiocytic markers CK7 and CK19,
and there does not appear to be any Notch involvement in tumors undergoing hypoxia at ad-
vanced stages, might reflect this HCC trans-differentiation rather than LPC involvement. How-
ever, while whole liver analysis showed no Notch- pathway activation, individual cell
populations should be analyzed for more clarity on Notch involvement.
The present study underlines that early hypoxic stimuli have detrimental effects on tumor
progression with an increased expression of poor prognostic markers later on. Activation of
the HIF pathway at advanced stages of tumorigenesis resulted in severely increased expression
of LPC characteristics without Notch activation. Hypoxic treatment at intermediate stages of
DEN induced hepatocarcinogenesis appears to have the least detrimental effect on tumor pro-
gression and reflects the advantages of early tumor diagnosis with most favorable treatment op-
tions/effects.
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